A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons

Inclusion Criteria Concurrent Medication: Allowed: * Other medically indicated vaccinations, provided they are administered at least 2 weeks before or after any study injection. * Alcohol use limited to 1 oz per day of 100 proof. Patients must have: * HIV infection without evidence of AIDS. * CD4 count \> 500 cells/mm3. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Current evidence of underlying lung or liver disease. * Suspected or diagnosed allergy to any vaccine component. * Medical contraindication to protocol participation. * Undergoing allergy skin testing or desensitization. Concurrent Medication: Excluded: * Antiretroviral therapy (unless clinically indicated and with approval of investigator). * Immunosuppressive or immunomodulatory therapy. * Nonsteroidal anti-inflammatory agents (except short-term therapy for acute conditions). * Drugs with known hepatotoxicity. * Alcohol intake \> 1 oz per day of 100 proof. Patients with the following prior conditions are excluded: * History of underlying lung disease. * Abnormal chest radiograph within 2 weeks prior to first vaccine injection. * History of underlying liver disease. * Abnormal hepatitis B surface antigen or hepatitis C antibody test within 2 weeks prior to first vaccine injection. * Abnormal liver function tests within 30 days prior to study entry. * Evidence of uveitis by slit lamp exam within 2 weeks prior to study entry. * Anergic as evidenced by negative skin test responses to all three antigens in a panel consisting of tetanus toxoid, mumps, and Candida albicans, within 6 weeks prior to first vaccine injection. * Prior participation on an HIV vaccine trial. Prior Medication: Excluded within the past 3 months: * Antiretroviral therapy. * Immunosuppressive drugs. * Alpha interferon or any immunomodulatory drugs. * Any investigational HIV drugs or therapies. Current alcohol abuse.